Review: Catechol O-methyl transferase inhibitors plus L-dopa and some surgical interventions improve Parkinson disease symptoms

March 2004
ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p42
Academic Journal
The article examines if pharmacologic, surgical, psychiatric, or ancillary interventions can improve symptoms in patients with early or advanced Parkinson disease (PD). Studies were selected if they were randomized controlled trials (RCTs) of pharmacologic, psychiatric, surgical, or ancillary interventions. Main pharmacologic outcomes were standardized mean change scores on the Unified Parkinson Disease Rating Scale. It was found in patients with advanced Parkinson disease, catechol O-methyl transferase inhibitors improve symptoms, and deep brain stimulation and fetal cell transplantation reduce on scores.


Related Articles

  • Review: Catechol O-methyl transferase inhibitors plus L-dopa and some surgical interventions improve Parkinson disease symptoms: COMMENTARY. Jog, Mandar // ACP Journal Club;Mar/Apr2004, Vol. 140 Issue 2, p42 

    The article comments on a study conducted to study the efficacy of different medical interventions to improve the symptoms in patients with early or advanced Parkinson disease (PD). The study reviewed current PD treatment, including pharmacologic, physiotherapeutic, surgical, and psychiatric...

  • Istradefylline: An adenosine receptor antagonist for the treatment of Parkinson disease. Pomfret, Thomas C.; Gagnon, James; Pietarinen, Jaclyn // Formulary;May2008, Vol. 43 Issue 5, p157 

    Parkinson disease (PD) is a chronic and progressive neurologic disorder with a prevalence that may be as high as 329 cases per 100,000 population. This movement disorder involves a gradual decline in the neurotransmitter dopamine, which is responsible for facilitating smooth muscle and...

  • Tolcapone: return to market.  // WHO Drug Information;2005, Vol. 19 Issue 1, p33 

    The article reports that Tolcapone is a catechol- O-methyltransferase (COMT) inhibitor medicine developed for use in Parkinson disease. In February 1999, the British Committee on Safety of Medicines reported the withdrawal of tolcapone following serious hepatic reactions and neuroleptic...

  • Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol- O-methyltransferase inhibition in Parkinson's disease patients. Müller, Thomas; Muhlack, Siegfried // Journal of Neural Transmission;Jun2014, Vol. 121 Issue 6, p643 

    Oxidative stress is influenced by the thiol homeostasis, which regulates the redox milieu via glutathione. Components of glutathione metabolism are cysteine and cysteinyl-glycine. Both substrates decay following levodopa application or dopamine-related oxidative stress. Objective was to...

  • Screening of Some Plant-Derived Alkaloids and Phenolics for Catechol-OMethyltransferase Inhibition. YALÇIN, Dilek; BAYRAKTAR, Ouz // International Journal of Natural & Engineering Sciences;May2009, Vol. 3 Issue 2, p21 

    The purpose of this study was to screen natural compounds extracted from plant species (Peganum harmala, Pistacia terebinthus, Sarcopterium spinosum, Pistacia lentiscus, Hypericum empetrifolium) as medicine alternates in order to investigate the inhibition characteristics on...

  • Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol- O-methyltransferase inhibition. Muhlack, Siegfried; Herrmann, Lennard; Salmen, Stephan; Müller, Thomas // Journal of Neural Transmission;Nov2014, Vol. 121 Issue 11, p1357 

    Catechol- O-methyltransferase inhibitor addition to levodopa/carbidopa formulations improves motor symptoms and reduces levodopa fluctuations in patients with Parkinson's disease. Objectives were to investigate the effects of entacapone and tolcapone on plasma behaviour of levodopa, its...

  • Gene-based Therapies in Parkinson's Disease. Allen, Patricia; Feigin, Andrew // Neurotherapeutics;Jan2014, Vol. 11 Issue 1, p60 

    Parkinson's disease (PD) is a progressive neurological disorder characterized primarily by the degeneration of nigrostriatal dopaminergic neurons and diminution of the neurotransmitter dopamine. Though dopamine replacement therapies such as levodopa can improve the symptoms of PD, the benefits...

  • Angiotensin blockade for diabetes: Monitor microalbuminuria? Muench, John; Blenning, Carol // Journal of Family Practice;Feb2007, Vol. 56 Issue 2, p145 

    The article discusses the effect of continued screening for microalbuminuria in patients taking an angiotensin-converting enzyme inhibitor or angiotensin-2 receptor blocker. It has been inferred that the effect of the screening improves outcomes in patients. According to experts, it may be...

  • Rasagiline and Parkinson's disease.  // Critical Care Alert;Nov2009 Pharmacology, p2 

    The article focuses on the study concerning the effect of rasagiline on the slow progression of Parkinson's disease which concludes that early treatment with one milligram dose of rasagiline per day shows a possible disease-modifying effect.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics